“We now have had begin to the monetary 12 months with a gradual all-round efficiency…,” Piramal Pharma Chairperson Nandini Piramal mentioned. Illustration: Ajay Mohanty
Piramal Pharma Ltd on Friday reported a narrowing of consolidated web loss at Rs 88.64 crore within the first quarter that ended June 30, 2024, on the again of upper gross sales.
The corporate had posted a consolidated web lack of Rs 98.58 crore in the identical quarter final fiscal, Piramal Pharma mentioned in a regulatory submitting.
Consolidated income from operations within the quarter beneath assessment stood at Rs 1,951.14 crore as in comparison with Rs 1,748.85 crore within the year-ago interval, the corporate added.
Whole bills within the first quarter have been greater at Rs 2,038.16 crore as in comparison with Rs 1,908.66 crore in the identical interval a 12 months in the past.
“We now have had begin to the monetary 12 months with a gradual all-round efficiency…,” Piramal Pharma Chairperson Nandini Piramal mentioned.
The corporate’s CDMO (Contract Improvement and Manufacturing Organisation) enterprise continues to witness sustained order inflows, particularly for on-patent industrial manufacturing, she added.
“We’re additionally seeing good demand for our differentiated choices with a rise in buyer enquiries and visits. In our CHG (Complicated Hospital Generics) enterprise, our deliberate enlargement for inhalation anaesthesia portfolio is on monitor and is predicted to get commercialised in FY26,” Piramal mentioned.
(Solely the headline and film of this report could have been reworked by the Enterprise Commonplace workers; the remainder of the content material is auto-generated from a syndicated feed.)
First Printed: Jul 26 2024 | 11:30 PM IST
